MedPath

Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty

Not Applicable
Completed
Conditions
Pain
Interventions
Procedure: QLB bloc
Drug: 0.9% normal saline
Registration Number
NCT02932930
Lead Sponsor
St Joseph University, Beirut, Lebanon
Brief Summary

The original concept of a quadratus lumborum block (QLB) indicated for analgesia after abdominal surgery was first described by Blanco in 2007. Also referred to as a posterior transversus abdominis plane (TAP) block, the QLB consists in deposition of local anesthetic on either the posterior or the anterolateral border of the quadratus lumborum muscle. TAP blocks have already been proved effective in urologic, abdominal, and gynecologic procedures by blocking the sensory nerve supply to the anterior abdominal wall thus reducing the amount of postoperative analgesic medication. The main advantages of QLB compared to the TAP block is a wider sensory block area and a longer duration of analgesia. This is due to the extension of local anesthetic agents beyond the TAP plane to the thoracic paravertebral space(4).

Previous reports have shown that QLB is effective in providing pain relief after various abdominal operations. However, there are no published reports on QLB for postoperative pain after abdominoplasty. This prospective, randomized, double-blinded, controlled study aims to evaluate the analgesic efficacy, opioids consumption and quality of recovery of QLB in patients undergoing abdominoplasty. Patients scheduled to have abdominoplasty will be randomized to receive bilateral QLB with either ropivacaine 0.2% or normal saline. Post-operative cumulative analgesic medication consumption, pain severity at rest and on movement, as well as quality of recovery will be evaluated and compared in both groups.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  1. Standard abdominoplasty procedure
  2. Written informed consent
  3. Age ≥ 18 years
  4. Female
Exclusion Criteria
  1. Patient's refusal
  2. Allergies to any study medication
  3. Inability to comprehend or participate in scoring scales
  4. Deformations that could possibly affect the spread of the local anesthetic in the quadratus lumborum muscle plane
  5. Quadratus lumborum muscle plane not seen in ultrasound examination
  6. Coagulopathy or on anticoagulants

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
QLB group0.2% RopivacainePatients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine
Control group0.9% normal salinePatients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline
QLB groupQLB blocPatients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine
Control groupQLB blocPatients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline
Primary Outcome Measures
NameTimeMethod
Cumulative morphine consumptionup to 48 hour

Cumulative morphine consumption in mg while in the PACU and tramadol dose till 48 hour post operatively.

Secondary Outcome Measures
NameTimeMethod
Time to first tramadol doseup to 48 hour

Time to first tramadol dose: time from the discharge to the surgical ward to the first postoperative subcutaneous tramadol dose requested by the patient.

Postoperative pain severityup to 48 hour

Postoperative pain severity in Numerical Rating Scale at rest in the first 48 hour after surgery. Ranging from 0 for no pain to 10 for worst pain imaginable. All patients will be assessed postoperatively by a blinded investigator: at 2, 4, 6, 12, 24, 36, and 48 hour postoperatively.

Quality of recoveryup to 48 hour

Quality of recovery using the self-assessment quality of recovery (QoR) scale to assess the patient's recovery quality

Postoperative dynamic pain severityup to 48 hour

Postoperative dynamic pain severity (walking, coughing, deep breathing) in Numerical Rating Scale in the first 48 hour after surgery. Ranging from 0 for no pain to 10 for worst pain imaginable. All patients will be assessed postoperatively by a blinded investigator: at 2, 4, 6, 12, 24, 36, and 48 hour postoperatively.

Nausea or vomitingup to 48 hour

Nausea or vomiting up to 48h post operatively (2, 4, 6, 12, 24, 36, and 48 hour postoperatively) using the following four grades scale:

0 = No nausea; 1 = Mild nausea; 2 = Moderate nausea; 3 = Severe nausea or vomiting

Sedation levelup to 48 hour

Sedation level up to 48 hour post operatively using the following Ramsay score.

Time to first walkup to 48 hour

Time to first walk

Trial Locations

Locations (1)

Hotel Dieu De France

🇱🇧

Beirut, Aschrafieh, Lebanon

© Copyright 2025. All Rights Reserved by MedPath